Approval marks first combined indication label and first regulatory approval in the world for UVADEX in conjunction with the THERAKOS Extracorporeal Photopheresis (ECP) System for the treatment of chronic GvHD...
Read More
2020 award open for entries for a chance to win €50,000 -- Investigator Award recognises individuals making a difference and reinforces company's ongoing commitment to the science of immunomodulation through...
Read More
Retrospective study shows that ECP when added to standard local therapy improves survival probability by approximately 30% in lung transplant patients diagnosed with BOS compared to matched controls -- Adjunct...
Read More
€50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust STAINES-UPON-THAMES, England, March 26, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today...
Read More
Collaboration with experts in photopheresis field expected to further enhance understanding of photopheresis' effect on immune modulation across a range of severe and critical conditions Agreement includes joint development activities...
Read More
Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol BEDMINSTER, N.J., Feb. 20, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE:MNK), a leading global...
Read More